Williams, Hadyn, M.D.
Associate Member, Clinical Oncology Program
Associate Professor, Rediology
GRU Cancer Center
Hadyn T. Williams, MD, FACNM, is Associate Professor of Diagnostic, Therapeutic, and Interventional, Radiology; Nuclear Medicine Section; Medical College of Georgia (MCG). Dr. Williams earned his M.D. (1981) from The University of South Alabama College of Medicine in Mobile, Alabama; did internship/residency/fellowship in internal medicine/diagnostic radiology/nuclear medicine/pediatric nuclear medicine in Los Angeles, CA, at the Wadsworth VA Medical Center/University of California Los Angeles/Cedars Sinai Medical Center/Children’s Hospital of Los Angeles; and was at the Philadelphia VA Medical Center/University of Pennsylvania and Atlanta Medical Center/VA Atlanta/Emory University prior to coming to MCG in 2002.
At MCG, Dr. Williams is Chair of the Medical Center and Medical College Radiation Safety Committees, Principal Authorized User for the Medical Center and Medical College Institutional Broad-Scope Radioactive Materials Licenses for numerous Research Protocols from the Cancer Center, Hematology/Oncology, Gynecologic Oncology, and Cardiology. He is Past-President of the American College of Nuclear Medicine (ACNM) and of the Southeastern Chapter of the Society of Nuclear Medicine (SNM), Fellow of the ACNM, and has served on numerous Committees, Councils, and as Representative for the American Medical Association, American College of Radiology, ACNM, SNM, MCG, Physicians Practice Group, Georgia Medicare Carrier Advisory Committee representing Nuclear Medicine; and is on the Editorial Board of Clinical Nuclear Medicine and Reviewer for an additional five journals. He is Board Certified by the American Board of Nuclear Medicine, and in 2007, was named Distinguished Scientist of the Year by the Citizens for Nuclear Technology Awareness, an advocate for Savannah River National Laboratory, US Department of Energy.
Dr. Williams has been active in clinical research from the start of his career, having published &/or presented over 200 papers or book chapters. These involved preclinical trials of radiopharmaceuticals, clinical utility of nuclear medicine procedures, and trials evaluating nuclear medicine and radiographic imaging in diagnosis, staging, prognosis, restaging, and assessment of response to treatment in disease states. He is MCG’s Principal Investigator for the American College of Radiology Imaging Network (ACRIN), a Cooperative Group of the National Cancer Institute, National Institutes of Health, “Gynecologic Tumor Imaging with Positron Emission Tomography (PET) and Computed Tomography (CT)” trial and the “PET/CT Imaging as Predictor of Tumor Response and Patient Outcome in Lung Cancer” trial, and for the “Phase III PET Myocardial Perfusion Imaging (F-18 flurpiridaz) with Coronary Artery Disease” trial.
Through the tracer kinetic model, PET offers examination of a wide number of physiologic, biochemical, and cell signaling pathways. Nuclear Medicine Imaging has been instrumental in evaluation of stem cell transplant efficacy and applicability, including mesenchymal stem cell targeting of microscopic tumors for anticancer gene therapy, monitoring of autologous bone marrow stem cells in myocardial incorporation and effect on ventricular function following infarction, and tracking the fate of transplanted cardiac stem cells participating in cardiac regeneration by observation of living cells. In conjunction with the MCG Nuclear Medicine Section, the Core Imaging Facility for Small Animals under direction of medical physicist Dr. Nathan Yanasak provides mechanisms for preclinical imaging.